Current Report Filing (8-k)
November 10 2021 - 4:07PM
Edgar (US Regulatory)
false00-00000000001534248NASDAQNASDAQ00015342482021-11-102021-11-100001534248cmmb:AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember2021-11-102021-11-100001534248cmmb:OrdinarySharesNoParValuePerShareMember2021-11-102021-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2021
Chemomab Therapeutics Ltd.
(Exact name of Registrant as Specified in Its Charter)
Registrant’s telephone number, including area code: +972-77-331-0156
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
* Not for trading; only in connection with the registration of American Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated into this Item 7.01 by reference,
is an updated corporate presentation of the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Apr 2024 to May 2024
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Anchiano Therapeutics Ltd (NASDAQ): 0 recent articles
More Chemomab Therapeutics Ltd. News Articles